CRPHAGE

Serial Number 88171376
Registration 6615709
700

Registration Progress

Application Filed
Oct 26, 2018
Under Examination
May 14, 2019
Approved for Publication
Mar 19, 2019
Published for Opposition
Mar 19, 2019
Registered
Jan 11, 2022

Trademark Image

CRPHAGE

Basic Information

Serial Number
88171376
Registration Number
6615709
Filing Date
October 26, 2018
Registration Date
January 11, 2022
Published for Opposition
March 19, 2019
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Jan 11, 2022
Registration
Registered
Classes
042

Rights Holder

Locus Biosciences, Inc.

03
Address
Suite 350
523 Davis Drive
Morrisville, NC 27560

Ownership History

Locus Biosciences, Inc.

Original Applicant
03
Research Triangle Park, NC

Locus Biosciences, Inc.

Owner at Publication
03
Morrisville, NC

Locus Biosciences, Inc.

Original Registrant
03
Morrisville, NC

Legal Representation

Attorney
Chelsea E. Carbone

USPTO Deadlines

Next Deadline
889 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2022-01-11)
Due Date
January 11, 2028
Grace Period Ends
July 11, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

35 events
Date Code Type Description Documents
Jan 11, 2022 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Dec 8, 2021 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Dec 7, 2021 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Nov 20, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Nov 19, 2021 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Nov 19, 2021 EX5G S SOU EXTENSION 5 GRANTED Loading...
Nov 19, 2021 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Nov 12, 2021 IUAF S USE AMENDMENT FILED Loading...
Nov 12, 2021 EXT5 S SOU EXTENSION 5 FILED Loading...
Nov 12, 2021 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Nov 12, 2021 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
May 12, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 10, 2021 EX4G S SOU EXTENSION 4 GRANTED Loading...
May 10, 2021 EXT4 S SOU EXTENSION 4 FILED Loading...
May 10, 2021 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Oct 29, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Oct 27, 2020 EX3G S SOU EXTENSION 3 GRANTED Loading...
Oct 27, 2020 EXT3 S SOU EXTENSION 3 FILED Loading...
Oct 27, 2020 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 14, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 12, 2020 EX2G S SOU EXTENSION 2 GRANTED Loading...
May 12, 2020 EXT2 S SOU EXTENSION 2 FILED Loading...
May 12, 2020 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 28, 2019 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 26, 2019 EX1G S SOU EXTENSION 1 GRANTED Loading...
Aug 26, 2019 EXT1 S SOU EXTENSION 1 FILED Loading...
Aug 26, 2019 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 14, 2019 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Mar 19, 2019 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Mar 19, 2019 PUBO A PUBLISHED FOR OPPOSITION Loading...
Feb 27, 2019 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Feb 4, 2019 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Feb 3, 2019 DOCK D ASSIGNED TO EXAMINER Loading...
Nov 10, 2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Oct 30, 2018 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 042
Pharmaceutical research and development; research and development in pharmacology for the purpose of targeting and destroying bacteria; medical research for use in treating antibiotic-resistant bacterial infections and microbiome-related disorders; medical and scientific research; pharmaceutical research in the field of engineered bacteriophage; pharmaceutical research using engineered therapeutics for use in antibacterial drug development; pharmaceutical research, namely, research relating to engineered bacteriophage platforms for improving pharmacological properties; pharmaceutical research, namely, research relating to engineered bacteriophages for use in connection with a wide variety of therapeutic agents
First Use Anywhere: Jan 2, 2019
First Use in Commerce: Jan 2, 2019

Classification

International Classes
042